New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
04:55 EDTGLYC, GLYC, GLYCGlycoMimetics management to meet with Jefferies
Meetings to be held in the Mid-Atlantic area July 28-29 hosted by Jefferies.
News For GLYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
08:14 EDTGLYCBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 19, 2015
09:30 EDTGLYCGlycoMimetics initiates Phase 1/2 clinical trial of GMI-1271
GlycoMimetics announced that the first patient has been dosed in a Phase 1/2 clinical study designed to evaluate the safety, pharmacokinetics and efficacy of GMI-1271, a novel and proprietary E-selectin antagonist in the company’s pipeline, when used in combination with chemotherapy in patients with acute myeloid leukemia. GlycoMimetics is initially exploring the clinical use of the drug candidate in hematologic malignancies following the successful completion of a Phase 1 healthy volunteer study late last year. The company announced last week that the U.S. FDA has granted Orphan Drug designation to GMI-1271 for treatment of AML. This Phase 1/2, open-label multicenter study is designed to determine safety, PK and efficacy of GMI-1271 in combination with chemotherapy in male and female adult patients with AML. Study sites are located in the United States, Australia and Ireland. While the primary objective is to analyze safety, additional endpoints include: mobilization of AML blasts, effect on neutropenia, time to and duration of remission, evaluation of event-free survival and evaluation of the overall survival probability at six- and 12-months. Approximately 77 subjects will be enrolled. The study will include a dose escalation phase followed by expansion of the study once the dose for the Phase 2 portion has been selected.
May 14, 2015
10:31 EDTGLYCGlycoMimetics granted orphan drug designation for GMI-1271 for treatment of AML
Subscribe for More Information
09:03 EDTGLYCGlycoMimetics receives orphan status for AML treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use